COVID-19
Conditions
Keywords
Hemostasis
Brief summary
Coronavirus COVID-19 is an emerging virus also called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Eighty percent of patients are poor or asymptomatic. However, there are major respiratory complications for some patients, requiring intensive care hospitalization and possibly leading to death in 5% of cases. One of the hypotheses put forward is that much of the pathophysiology is due to endothelial dysfunction associated with disseminated intravascular coagulation. The covid-19 pathology could induce coagulation impairment as observed during sepsis. An increase in D-dimer levels during covid-19 disease is itself associated with excess mortality. While D-dimers are highly sensitive, they are not specific for clotting activity. They may be increased in many other circumstances, particularly in inflammation. On the other hand, the infection stimulates the release of extracellular vesicles. These vesicles, of multiple cellular origin, are an actor of vascular homeostasis, and participate in the state of hyperactivation of coagulation. They have a major role in the prothrombotic state and the development of coagulopathy associated with sepsis. The aim of our monocentric prospective study would be to study early and more specific markers of hypercoagulability and markers of routine endothelial dysfunction, as soon as the patient is hospitalized, in order to predict the risk of hospitalization in intensive care.
Interventions
PROCEDUREblood sampling
blood sampling in hospitalized patient for COVID-19 infection
Sponsors
University Hospital, Rouen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any adult patient admitted to Rouen University Hospital for documented SARS-Cov-2 infection (PCR Test or CT scan) * Patient who accept to participate to research after reading the information note * Patient affiliated with Social Security
Exclusion criteria
* Patient under protective guardianship or curatorship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical worsening (yes/no) of the patient during hospitalization | in the 15 days from admission | — |
| D-DIMERS plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Fibrin monomers plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Antithrombin plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Prothrombin Fragment 1 plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Prothrombin Fragment 2 plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Thrombin generation test plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Microvesicles of platelet plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Cross-linked platelets plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Willebrand Factor plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
| Factor VIII plasma levels in blood | 1 hour after admission | Biological analysis using initial blood sampling |
Countries
France
Outcome results
None listed